Biotech
-
J&J joins Pfizer in detailing impact of Part D redesign
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction…
Read More » -
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat…
Read More » -
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete…
Read More » -
‘The bar has risen’: China’s biotech gains push US companies to adapt
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and…
Read More » -
Lilly blames slower-than-expected growth for 2024 sales miss
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further…
Read More » -
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate…
Read More » -
Patrizia Cavazzoni, key FDA official, to leave agency
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to…
Read More » -
FDA adds warning to RSV shots from GSK, Pfizer
The regulator is requiring labeling that warns of Guillan-Barré syndrome, although it said data don’t prove a causal link and…
Read More » -
Orbis raises $93M to turn popular biologics into pills
The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against “validated blockbuster biologic…
Read More » -
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data…
Read More »